MRC1 and neoplasm: Providers might also erroneously consider that the absence of tumor dMMR negates the value of MGPT, which can detect MMR PVs in some MMR proficient cases as well as PVs in non-Lynch cancer susceptibility genes (about 7% of all CRC patients)27.